For millions of people worldwide, GLP-1 receptor agonists have transformed the approach to treating type 2 diabetes and obesity. However, for those planning a family, these medications have long been shrouded in a layer of clinical caution. Because of a lack of large-scale human data, the standard medical advice has been clear: discontinue these drugs well before conception.
New evidence is now beginning to challenge that void of information. A comprehensive systematic review led by researchers at the University of St Andrews suggests that exposure to GLP-1 receptor agonists around the time of pregnancy does not appear to increase the risk of major birth defects. This finding provides a critical, albeit cautious, piece of the puzzle for clinicians and patients navigating the intersection of metabolic health and prenatal care.
The study, published in the American Journal of Obstetrics and Gynaecology, represents the largest analysis of its kind. By synthesizing data from more than 49,000 pregnancies over a 20-year period, the researchers aimed to determine if these medications—which include widely known brands like Ozempic and Wegovy—posed a significant risk of congenital malformations.
As a physician and journalist, I have watched the meteoric rise of semaglutide and its counterparts with a mix of professional admiration and clinical vigilance. While the weight-loss and glycemic results are undeniable, the “known unknowns” regarding fetal development have remained a primary concern in internal medicine and obstetrics. This new data does not yet rewrite the rulebooks, but it does offer a evidence-based breath of relief.
The St Andrews Study: Breaking Down the Data
The scale of this systematic review is what distinguishes it from previous, smaller observational reports. By analyzing a cohort of more than 49,000 pregnancies
spanning two decades, the University of St Andrews team was able to look past the noise of individual case studies to find broader patterns in how GLP-1 receptor agonists affect fetal development.
The primary focus of the research was the incidence of major birth defects—structural abnormalities that significantly impact the health or viability of the fetus. After reviewing the available data, the researchers found no statistically significant increase in these defects among pregnancies exposed to GLP-1s compared to those that were not. This suggests that the perceived risk may have been higher than the actual clinical reality in human populations.
It is important to understand that this was a systematic review, meaning the researchers gathered and analyzed existing data from multiple sources rather than conducting a new clinical trial. While this provides a powerful overview of real-world usage, it differs from a randomized controlled trial (RCT), which is the gold standard for establishing absolute safety.
Why the Caution? The History of GLP-1s and Pregnancy
To understand why this study is significant, one must understand why the medical community has been so hesitant. GLP-1 (glucagon-like peptide-1) receptor agonists mimic a hormone that regulates insulin secretion and slows gastric emptying, which leads to increased satiety and weight loss. While these effects are beneficial for adults, the developmental environment of a fetus is incredibly sensitive to hormonal and metabolic shifts.
Historically, caution was driven by two main factors:
- Animal Data: Early studies in animal models sometimes showed adverse effects on fetal growth or development, leading researchers to apply the precautionary principle to humans.
- Lack of Human Trials: For ethical reasons, pregnant women are almost never included in the initial clinical trials for new medications. This creates a “data gap” where the only information available comes from accidental exposures or women who did not stop their medication before conceiving.
Because of this gap, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) generally advise that these medications should not be used during pregnancy. The current clinical consensus is that the potential risks to the fetus outweigh the benefits of the drug during gestation, especially since there are other, more established ways to manage blood glucose during pregnancy, such as insulin.
The Balancing Act: Obesity, Diabetes, and Pregnancy
The conversation around GLP-1 receptor agonists and pregnancy safety is not just about the drugs themselves, but about the conditions they treat. Obesity and uncontrolled type 2 diabetes are not benign during pregnancy. they are associated with a range of complications, including:
- Gestational Diabetes: Which can lead to macrosomia (excessive birth weight) and neonatal hypoglycemia.
- Preeclampsia: A dangerous increase in blood pressure that can threaten both the parent and the fetus.
- Increased C-section Rates: Higher metabolic risks often correlate with more complex deliveries.
For some patients, the risk of uncontrolled obesity or diabetes during pregnancy may be as concerning as the theoretical risk of the medication. This is where the St Andrews study becomes a vital tool for shared decision-making. When a patient accidentally becomes pregnant while on a GLP-1, or when a clinician is weighing the risks of a sudden medication switch, having data on 49,000 pregnancies provides a much more stable foundation for guidance than anecdotal evidence.
Clinical Implications: What This Means for Patients
Despite the encouraging findings of the systematic review, the medical community is not yet pivoting to a recommendation of safe use
during pregnancy. Instead, the tone is one of cautious optimism
. The findings suggest that the risk of major malformations is likely low, but they do not prove that these drugs are entirely without effect on fetal development.
For those currently using GLP-1 receptor agonists who are planning a pregnancy, the following guidelines generally remain in place:
Consultation is Mandatory: No one should stop or change their medication dosage without the direct supervision of their endocrinologist or obstetrician. Stopping a GLP-1 abruptly can cause a spike in blood glucose levels, which is itself a risk factor for fetal health.
The Transition Plan: Many physicians recommend transitioning patients from GLP-1s to insulin several weeks or months before attempted conception. Insulin is generally considered the safest option for glycemic control during pregnancy because it does not cross the placenta in significant amounts and has decades of safety data.
Accidental Exposure: For those who discover they are pregnant while already taking a GLP-1, this study provides a critical point of reassurance. Rather than panicking, patients can discuss the low statistical risk of major birth defects with their healthcare provider and plan a safe transition to alternative therapies.
Looking Ahead: The Need for Prospective Research
The transition from suggesting safety
to confirming safety
requires a different kind of evidence. The next step for the scientific community is the development of prospective registries. By tracking women who are intentionally or unintentionally exposed to GLP-1s during pregnancy in a structured way, researchers can look for more subtle outcomes beyond major birth defects, such as birth weight, neurodevelopmental milestones, and long-term metabolic health of the child.
As we move deeper into 2026, the prevalence of these drugs continues to grow. It is inevitable that more pregnancies will occur while patients are on these medications. The goal now is to move from reactive data collection to proactive monitoring.
Key Takeaways on GLP-1s and Pregnancy
| Factor | Current Status / Finding |
|---|---|
| Major Birth Defect Risk | No significant increase found in a review of 49,000+ pregnancies. |
| Current Regulatory Stance | Generally not recommended for use during pregnancy. |
| Primary Concern | Lack of prospective human RCTs; reliance on observational data. |
| Clinical Alternative | Insulin remains the gold standard for glycemic control in pregnancy. |
| Patient Action | Consult healthcare providers before changing medication for conception. |
The findings from the University of St Andrews are a significant milestone in reproductive medicine. They remind us that clinical caution is necessary, but it should be updated as the evidence evolves. For the millions of people balancing metabolic health with the desire for a healthy pregnancy, this research provides a much-needed bridge toward a more informed and less fearful future.
The medical community awaits further prospective data and updated guidance from global health regulators to determine if the clinical protocols for GLP-1 use will officially shift. Until then, the mantra remains: evidence-based caution and close clinical supervision.
Do you or a loved one navigate the balance between metabolic medications and family planning? We welcome your thoughts and experiences in the comments below. Please share this article with others who may find this updated research helpful.